

## FOI 4694 - NSCLC, Colorectal and Urothelial Cancer chemotherapy

Questions	Notes/Comments	Response			
<p>1) 1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the mentioned regimen names?</p>	<p>Included are all patients that received the requested chemotherapy between Nov -18 to April -19.</p>	<table border="1"> <thead> <tr> <th data-bbox="1198 411 1597 448">Regimen Name</th> <th data-bbox="1597 411 1870 448">Total Patients</th> </tr> </thead> </table>	Regimen Name	Total Patients	
		Regimen Name	Total Patients		
		Paclitaxel	0		
		Gemcitabine	0		
		Osimertinib	1		
		Carboplatin and Pemetrexed	2		
		Cisplatin and Pemetrexed	0		
		Pembrolizumab monotherapy	26		
		Pembrolizumab in combination	0		
		Ateolizumab	2		
		Nivolumab	0		
Otheractivesystemicanti-	21				

		cancertherapy	
		<b>Regimen Name</b>	<b>Total Patients</b>
<p><b>2 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the mentioned regimen names?</b></p>	<p>Included are all patients that received the requested chemotherapy between Nov -18 to April -19.</p>	Cetuximab not in combination with FOLFIRI or FOLFOX	12
		Cetuximab in combination with FOLFIRI	0
		Cetuximab in combination with FOLFOX	0
		Panitumumab not in combination with FOLFIRI or FOLFOX	0
		Panitumumab in combination with FOLFIRI	0
		Panitumumab in combination with FOLFOX	0
		Nivolumab	0
		Aflibercept	0
		Bevacizumab	0
		Ramucirumab	0
		Regorafenib	0

<p><b>3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Cancer with the following:</b></p>	<p>Included are all patients that received the requested chemotherapy between Nov -18 to April -19.</p>	Sorafenib	0
		<b>Regimen Name</b>	<b>Total Patients</b>
		Cisplatin single agent	0
		Cisplatin in combination with another agent	2
		Carboplatin single agent	0
		Carboplatin in combination with another agent	0
		Nivolumab	0
		Pembrolizumab	0
		Atezolizumab	0